JP2013534804A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534804A5
JP2013534804A5 JP2013505074A JP2013505074A JP2013534804A5 JP 2013534804 A5 JP2013534804 A5 JP 2013534804A5 JP 2013505074 A JP2013505074 A JP 2013505074A JP 2013505074 A JP2013505074 A JP 2013505074A JP 2013534804 A5 JP2013534804 A5 JP 2013534804A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
residue
alk
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013505074A
Other languages
English (en)
Japanese (ja)
Other versions
JP6223822B2 (ja
JP2013534804A (ja
Filing date
Publication date
Priority claimed from US12/761,050 external-priority patent/US8383793B2/en
Application filed filed Critical
Publication of JP2013534804A publication Critical patent/JP2013534804A/ja
Publication of JP2013534804A5 publication Critical patent/JP2013534804A5/ja
Application granted granted Critical
Publication of JP6223822B2 publication Critical patent/JP6223822B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013505074A 2010-04-15 2011-04-13 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物 Expired - Fee Related JP6223822B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/761,050 2010-04-15
US12/761,050 US8383793B2 (en) 2010-04-15 2010-04-15 Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
PCT/US2011/032204 WO2011130340A1 (en) 2010-04-15 2011-04-13 Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (alk) kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016195911A Division JP2017018141A (ja) 2010-04-15 2016-10-03 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2013534804A JP2013534804A (ja) 2013-09-09
JP2013534804A5 true JP2013534804A5 (cg-RX-API-DMAC7.html) 2014-05-29
JP6223822B2 JP6223822B2 (ja) 2017-11-01

Family

ID=44314994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013505074A Expired - Fee Related JP6223822B2 (ja) 2010-04-15 2011-04-13 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物
JP2016195911A Pending JP2017018141A (ja) 2010-04-15 2016-10-03 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016195911A Pending JP2017018141A (ja) 2010-04-15 2016-10-03 未分化リンパ腫キナーゼ(alk)キナーゼ阻害剤に耐性である癌の診断および治療のための方法および組成物

Country Status (10)

Country Link
US (2) US8383793B2 (cg-RX-API-DMAC7.html)
EP (1) EP2558490B1 (cg-RX-API-DMAC7.html)
JP (2) JP6223822B2 (cg-RX-API-DMAC7.html)
KR (1) KR20130064067A (cg-RX-API-DMAC7.html)
CN (1) CN103201286B (cg-RX-API-DMAC7.html)
AU (1) AU2011240636B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012026239A2 (cg-RX-API-DMAC7.html)
CA (1) CA2796306A1 (cg-RX-API-DMAC7.html)
RU (1) RU2012148450A (cg-RX-API-DMAC7.html)
WO (1) WO2011130340A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
DK2350075T3 (da) 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
EP2350071B1 (en) 2008-10-22 2014-01-08 Array Biopharma, Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US9528897B2 (en) 2009-08-13 2016-12-27 Chimden Medical Pty Ltd Pressure indicator
DK2918588T3 (en) 2010-05-20 2017-08-28 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
US20130288240A1 (en) * 2010-05-21 2013-10-31 Cell Signaling Technology, Inc. Alk and ros kinase in cancer
CA2825588C (en) 2011-02-02 2019-03-05 Umedaes Limited Improved artificial airway
EA201391626A1 (ru) 2011-05-04 2014-03-31 Ариад Фармасьютикалз, Инк. Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
ME02630B (me) 2012-03-06 2017-06-20 Pfizer Makrociklički derivati, namijenjeni liječenju proliferativnih bolesti
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
JP6205216B2 (ja) 2012-09-24 2017-09-27 アークレイ株式会社 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
EP3129477B1 (en) * 2014-04-10 2020-05-20 Memorial Sloan-Kettering Cancer Center A novel isoform of anaplastic lymphoma kinase and its uses
US9428812B2 (en) * 2014-04-28 2016-08-30 Insight Genetics, Inc. Kit comprising primers for amplifying ALK kinase domain nucleic acids
TWI767858B (zh) 2014-11-16 2022-06-11 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
WO2016115480A1 (en) * 2015-01-16 2016-07-21 Vedantra Pharmaceuticals, Inc. Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof
CA2987281A1 (en) * 2015-05-29 2016-12-08 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
SG11201803438XA (en) * 2015-10-26 2018-05-30 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE053643T2 (hu) 2016-05-18 2021-07-28 Loxo Oncology Inc (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése
CN107885972B (zh) * 2016-09-30 2021-07-27 广州华大基因医学检验所有限公司 一种基于单端测序的融合基因检测方法及其应用
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110716042A (zh) * 2019-10-23 2020-01-21 郑州大学 一种用于卵巢癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法
CN111235272B (zh) * 2020-01-10 2023-07-07 厦门艾德生物医药科技股份有限公司 一次性检测肺癌多重基因突变的组合物及其应用
BR112022021020A2 (pt) 2020-04-22 2023-02-14 Iovance Biotherapeutics Inc Método de fabricação de um produto de terapia celular, métodos de tratamento do paciente com o produto de terapia celular de expansão e fabricado, e, método de fabricação de um produto de terapia celular
CN112391390A (zh) * 2020-11-19 2021-02-23 山西大学 飞蝗网格蛋白重链基因及其靶向dsRNA的合成与应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0232967B1 (en) 1986-01-10 1993-04-28 Amoco Corporation Competitive homogeneous assay
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5107065A (en) 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5225326A (en) 1988-08-31 1993-07-06 Research Development Foundation One step in situ hybridization assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
AU633958B2 (en) 1989-07-25 1993-02-11 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
BR9106653A (pt) 1990-07-10 1993-06-08 Smithkline Beecham Corp Oxamidas
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
KR100236506B1 (ko) 1990-11-29 2000-01-15 퍼킨-엘머시터스인스트루먼츠 폴리머라제 연쇄 반응 수행 장치
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
CA2218875C (en) 1991-07-23 2000-11-07 The Research Foundation Of State University Of New York Improvements in the in situ pcr
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
US5545524A (en) 1991-12-04 1996-08-13 The Regents Of The University Of Michigan Compositions and methods for chromosome region-specific probes
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP1362913B1 (en) 1992-10-30 2006-01-25 The General Hospital Corporation Interaction trap system for isolating proteins
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US6696548B2 (en) * 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
JP3189000B2 (ja) 1994-12-01 2001-07-16 東ソー株式会社 特定核酸配列の検出方法
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5710029A (en) 1995-06-07 1998-01-20 Gen-Probe Incorporated Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6121489A (en) 1996-03-05 2000-09-19 Trega Biosciences, Inc. Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
EP0892808B1 (en) 1996-04-12 2008-05-14 PHRI Properties, Inc. Detection probes, kits and assays
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
EP1027456B1 (en) 1997-10-31 2005-03-16 Affymetrix, Inc. (a Delaware Corporation) Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
JP4646404B2 (ja) 1998-07-02 2011-03-09 ジェン−プローブ・インコーポレーテッド 分子トーチ(torch)
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6303305B1 (en) 1999-03-30 2001-10-16 Roche Diagnostics, Gmbh Method for quantification of an analyte
US6541205B1 (en) 1999-05-24 2003-04-01 Tosoh Corporation Method for assaying nucleic acid
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
CA2524572C (en) 2003-05-01 2018-07-10 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch having enhanced sensitivity to the presence of a mismatch
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP2042191B1 (en) * 2007-09-28 2013-01-02 Roberto Chiarle Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
TWI518325B (zh) * 2010-02-04 2016-01-21 自治醫科大學 對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療

Similar Documents

Publication Publication Date Title
JP2013534804A5 (cg-RX-API-DMAC7.html)
RU2012148450A (ru) Способы и композиции для диагностики и лечения рака, резистентного к ингибиторам киназы анапластической лимфомы (alk)
US12188096B2 (en) Clear cell renal cell carcinoma biomarkers
CN107002289B (zh) 用于定量评价dna-蛋白质复合物密度的组合物和方法
AU2018221704B2 (en) Transferrin receptor transgenic models
US10143187B2 (en) Transferrin receptor transgenic models
JP2015531590A5 (cg-RX-API-DMAC7.html)
JP2020536560A5 (cg-RX-API-DMAC7.html)
DK2715365T3 (en) ROSE KINASE IN LUNG CANCER
CA3150454A1 (en) Novel crispr dna targeting enzymes and systems
JP2010259438A5 (cg-RX-API-DMAC7.html)
CA2413475A1 (en) Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
RU2009135270A (ru) Способы выявления воспалительного заболевания кишечника
FI3774897T3 (fi) Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon
JP2014503180A5 (cg-RX-API-DMAC7.html)
JP2018148886A (ja) Cdk阻害剤と関連するバイオマーカー
JP2008512984A5 (cg-RX-API-DMAC7.html)
Loftus et al. Mechanism for G2 phase-specific nuclear export of the kinetochore protein CENP-F
JP2010528584A5 (cg-RX-API-DMAC7.html)
Kueng et al. Regulating repression: roles for the sir4 N-terminus in linker DNA protection and stabilization of epigenetic states
Bammert et al. JUNB O‐GlcNAcylation‐Mediated Promoter Accessibility of Metabolic Genes Modulates Distinct Epithelial Lineage in Pulmonary Fibrosis
JP2015502137A5 (cg-RX-API-DMAC7.html)
Mazzola et al. Inhibition of Yap2 activity by MAPKAP kinase Rck1 affects yeast tolerance to cadmium
JP2010131022A5 (cg-RX-API-DMAC7.html)
JP2013503644A5 (cg-RX-API-DMAC7.html)